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ABSTRACT The objective of this study was to investigate predisposing factors and
outcomes of infective endocarditis (IE) caused by non-HACEK Gram-negative bacilli
(GNB) in a contemporary multicenter cohort. Patients with IE due to GNB, prospec-
tively observed in 26 Italian centers from 2004 to 2011, were analyzed. Using a case-
control design, each case was compared to three age- and sex-matched controls
with IE due to other etiologies. Logistic regression was performed to identify risk
factors for IE due to GNB. Factors associated with early and late mortality were as-
sessed by Cox regression analysis. The study group comprised 58 patients with IE
due to GNB. We found that Escherichia coli was the most common pathogen, fol-
lowed by Pseudomonas aeruginosa and Klebsiella pneumoniae. The genitourinary
tract as a source of infection (odds ratio [OR], 13.59; 95% confidence interval [CI],
4.63 to 39.93; P  0.001), immunosuppression (OR, 5.16; 95% CI, 1.60 to 16.24; P 
0.006), and the presence of a cardiac implantable electronic device (CIED) (OR, 3.57;
95% CI, 1.55 to 8.20; P  0.003) were factors independently associated with IE due
to GNB. In-hospital mortality was 13.8%, and mortality rose to 30.6% at 1 year. A
multidrug-resistant (MDR) etiology was associated with in-hospital mortality (hazard
ratio [HR], 21.849; 95% CI, 2.672 to 178.683; P  0.004) and 1-year mortality (HR,
4.408; 95% CI, 1.581 to 12.287; P  0.005). We conclude that the presence of a geni-
tourinary focus, immunosuppressive therapy, and an indwelling CIED are factors as-
sociated with IE due to GNB. MDR etiology is the major determinant of in-hospital
and long-term mortality.
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In recent years, infections due to Gram-negative bacilli (GNB) have raised growingconcerns because of their increasing spread, high mortality, and high health care
costs. Non-HACEK (species other than Haemophilus species, Aggregatibacter actinomy-
cetemcomitans [previously known as Actinobacillus actinomycetemcomitans], Cardiobac-
terium hominis, Eikenella corrodens, and Kingella species) GNB are uncommon causes of
infective endocarditis (IE) (1). The International Collaboration on Endocarditis (ICE)
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study, a multinational IE registry, reported an incidence of endocarditis due to non-
HACEK GNB of approximately 2% (2). Available reports suggest that IE due to GNB is
associated with high in-hospital mortality (1, 3, 4). As with other bloodstream infections,
the frequency of IE caused by GNB from central catheter infection or in immunocom-
promised or elderly patients is on the rise (5). Moreover, the spread of multidrug-
resistant (MDR) strains is a growing concern worldwide (6–9). At present, however,
there are no specific clinical clues to the presence of IE in patients presenting with GNB
bacteremia. Furthermore, when empirical antimicrobials should cover possible GNB in
patients presenting with IE remains unknown.
Hence, the aim of this study was to identify factors associated with endocarditis due
to non-HACEK GNB and to describe the outcomes for these patients in a large
contemporary multicenter cohort of patients.
RESULTS
Of the 1,722 patients included in the Italian Endocarditis Study (SEI) database, 72
had IE due to GNB. Four patients had a HACEK group etiology and were subsequently
excluded. Among the remaining 68 patients (3.9% of all episodes), 10 had polymicrobial
infections (9 cases of IE due to mixed Gram-negative and Gram-positive bacteria and 1
case with mixed GNB and Candida spp.) and were also excluded from the analysis. Thus,
the final cohort comprised 58 patients. A flow chart of the study is shown in Fig. 1.
Table 1 and Fig. S1 in the supplemental material show the species distribution of the
causative pathogens of IE due to non-HACEK GNB. The most common etiologies were
Escherichia coli (18 episodes [31%]), Pseudomonas aeruginosa (11 episodes [19%]), and
Klebsiella pneumoniae (6 episodes [10.3%]). Three patients (5.2%) had polymicrobial IE
due to GNB (more than 1 GNB isolated). The percentage of MDR strains was 27.6%. The
median time between the start of symptoms and the diagnosis of IE due to GNB was
22 days (interquartile range [IQR], 8 to 39 days).
Predisposing factors for infective endocarditis due to non-HACEK GNB. As
shown in Table 2, patients with IE due to GNB were compared to 174 control patients. The
causative pathogens among controls were Staphylococcus aureus (48 cases [27.6%]),
coagulase-negative staphylococci (31 cases [17.8%]), enterococci (31 cases [17.8%], 24
with Enterococcus faecalis, 6 with Enterococcus faecium, and 1 with Enterococcus durans),
Streptococcus gallolyticus (29 cases [16.7%]), viridans group streptococci (26 cases
[14.9%]), Streptococcus agalactiae (4 cases [2.3%]), Candida spp. (2 cases [1.2%]), and
others (1.7%). Compared to matched controls, patients with IE due to GNB had a higher
FIG 1 Flow diagram of the study.
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prevalence of cardiac implantable electronic device (CIED)-related endocarditis, more
frequently had an indwelling central intravascular access device or a CIED at the time
of IE onset, showed a higher rate of diabetes mellitus, and were more likely to receive
concomitant immunosuppressive therapy. The genitourinary tract was the most fre-
quent source of infection in IE due to GNB. The appearance of new valve regurgitation
was significantly more common in controls than in patients with IE due to GNB (P 
0.007). Moreover, vegetations were larger in patients with IE due to GNB (14 mm [IQR,
6.5 to 20 mm]) than in controls (10 mm [IQR, 8 to 15 mm]) (P  0.027).
Upon multivariate analysis (Table 3), the genitourinary tract as a source of infection
(odds ratio [OR], 13.59; 95% confidence interval [CI], 4.63 to 39.93; P  0.001), immu-
nosuppression (OR, 5.16; 95% CI, 1.60 to 16.62; P  0.006), and the presence of a CIED
(OR, 3.57; 95% CI, 1.55 to 8.20; P  0.003) were factors independently associated with
IE caused by GNB, while the development of new valve regurgitation (OR, 0.39; 95% CI,
0.17 to 0.90; P  0.027) was a factor independently associated with IE due to other
etiologies.
Treatment and outcomes of patients with endocarditis due to non-HACEK GNB.
Table 4 describes the antibiotic regimens received by 58 patients with IE due to GNB.
Most patients received an antibiotic regimen (50%) containing penicillin or cephalo-
sporin (penicillin–penicillinase inhibitor or a third-generation cephalosporin, such as
ceftriaxone or ceftazidime), variably combined with an aminoglycoside or a fluoroquin-
olone. The second most frequently used regimen (22.4%) was the association of a
penicillin or cephalosporin and a carbapenem, with or without aminoglycosides or
fluoroquinolones. A substantial 27.6% of cases were treated with a carbapenem with or
without aminoglycosides, or a fluoroquinolone, or other antibiotics (including colistin).
Overall in-hospital mortality was 13.8% (all deaths were attributable to IE), while
1-year cumulative mortality was 30.6% (with a cumulative IE-related 1-year mortality of
22.4%). A comprehensive comparison between survivors and nonsurvivors is provided
in Table S1 in the supplemental material. Nonsurvivors had a higher median age, were
more likely to be affected by non-nosocomial health care-associated (HCA) IE and IE
TABLE 1 Etiologies of IE due to non-HACEK GNB
Etiology No. of patients (% of totala)
Enterobacteriaceae
Escherichia coli 18 (31)
Klebsiella pneumoniae 6 (10.3)
Citrobacter koseri 3 (5.2)
Proteus mirabilis 2 (3.5)
Serratia marcescens 2 (3.5)
Enterobacter spp. 2 (3.5)
Yersinia enterocolitica 1 (1.7)
Total 34 (58.6)
Nonfermenting bacteria
Pseudomonas spp. 11 (19)
Acinetobacter baumannii 1 (1.7)
Other bacteria
Campylobacter fetus 2 (3.5)
Fusobacterium spp. 2 (3.5)
Achromobacter xylosoxidans 1 (1.7)
Brucella spp. 1 (1.7)
Prevotella buccae 1 (1.7)
Raoultella spp. 1 (1.7)
Sphingomonas paucimobilis 1 (1.7)
GNB coinfectionsb 3 (5.2)
MDR etiology 16 (27.6)
aA total of 58 patients with IE due to non-HACEK GNB were studied.
bComprising one case with E. coli and Proteus mirabilis, one with Pseudomonas aeruginosa and Pseudomonas
fluorescens, and one with Pseudomonas aeruginosa and Stenotrophomonas maltophilia.
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TABLE 2 Comparison between patients with IE due to GNB (cases) and patients with IE
due to other etiologies
Variablea
Valueb for patients with IE due to:




Males 39 (67.2) 117 (67.6) 1.0
Median (range) age (yr) 69.5 (57.75–77) 69.5 (60–76) 1.0
Type of endocarditis
NVE 34 (58.6) 118 (67.8) 0.202
PVE 16 (27.6) 48 (27.6) 1.0
Device-related IE 8 (13.8) 8 (4.6) 0.017
Comorbidities
Diabetes 19 (32.8) 30 (17.2) 0.012
Hemodialysis 1 (1.7) 5 (2.9) 0.633
Malignancies 10 (17.2) 16 (9.2) 0.093
HIV infection 2 (3.4) 4 (2.3) 0.633
Risk factors
IVDU 5 (8.6) 15 (8.6) 1.0
Dental procedures 3 (5.2) 13 (7.5) 0.537
CVC 12 (20.7) 16 (10) 0.021
CIED 15 (25.9) 19 (10.9) 0.005
Congenital heart disease 4 (6.9) 10 (5.7) 0.758
Immunosuppression 9 (15.5) 7 (4) 0.003
Pre-existing valvular disease 18 (31) 57 (32.8) 0.808
Invasive procedures within 180 days
Dental procedures 3 (5.2) 13 (7.5) 0.537
Esophagogastroscopy 1 (1.7) 5 (2.9) 0.633
Colonoscopy 4 (6.9) 6 (3.4) 0.263
Cystoscopy 3 (5.2) 3 (1.7) 0.152
Route of acquisition
Community acquired 32 (55.2) 116 (66.7) 0.115
Healthcare associated 24 (41.4) 49 (28.2) 0.060
Nosocomially acquired 2 (3.4) 9 (5.2) 0.593
Complications
Stroke 7 (12.1) 27 (15.5) 0.520
Embolism 14 (24.1) 64 (36.8) 0.078
Heart failure 15 (25.9) 72 (41.4) 0.030
Septic shock 2 (3.4) 3 (1.7) 0.434
Arrhythmias 5 (8.6) 27 (15.5) 0.187
Echocardiographic findings
Evidence of vegetation 50 (86.2) 155 (89.1) 0.555
Median (range) size of vegetation (mm) 14 (6.5–20) 10 (8–15) 0.027
Cardiac abscess 3 (5.2) 17 (9.8) 0.280
Perforation 4 (6.9) 8 (4.6) 0.494
Dehiscence 6 (10.3) 9 (5.2) 0.165
New regurgitation 10 (17.2) 63 (36.2) 0.007
Fistula 0 (0) 4 (2.3) 0.244
Presumed source of infection
Genitourinary tract 16 (27.6) 6 (3.4) <0.001
Skin 8 (13.8) 28 (16.1) 0.675
Nonoral gastrointestinal tract 9 (15.5) 37 (21.3) 0.342
Oral 3 (5.2) 18 (10.3) 0.234
Other or unknown 24 (41.4) 81 (46.6) 0.493
Treatment (surgery plus antibiotic therapy) 25 (43.1) 79 (45.4) 0.760
(Continued on next page)
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due to MDR pathogens, and had a higher incidence of heart failure or septic shock.
Regarding antibiotic therapy, survivors were more frequently treated with a penicillin-
or cephalosporin-containing regimen (penicillin or cephalosporin with or without an
aminoglycoside), while nonsurvivors were more frequently treated with a regimen
containing a carbapenem (with or without an aminoglycoside). No significant mortality
differences between patients receiving antibiotic therapy alone and those undergoing
cardiac surgery were detected. However, among 21 patients with complications (in-
cluding the development of a cardiac abscess, fistula, dehiscence, valve perforation, or
de novo heart failure), those receiving medical therapy alone (n  10) showed higher
mortality rates than those undergoing surgery (n  11) (60% versus 18.2%, respectively;
P  0.049 [data not shown]). Upon Cox regression analysis (Table 5), an MDR etiology
was the only factor independently associated with in-hospital mortality (hazard ratio
[HR], 21.849; 95% CI, 2.672 to 178.683; P  0.004). Of 50 patients who survived the initial
hospitalization, 41 (82%) were followed for as long as 1 year after hospitalization; of
these, 7 (17%) patients died during the 1-year follow-up. Thus, the cumulative 1-year
mortality amounted to 15 (30.6%) patients. As shown in Table 5, MDR etiology was
confirmed to be an independent factor associated with 1-year mortality (HR, 4.408; 95%
CI, 1.581 to 12.287; P  0.005). Figure 2 shows the Kaplan-Meier in-hospital (Fig. 2A) and
1-year (Fig. 2B) survival curves of patients with IE due to MDR GNB and those with IE
due to susceptible GNB.
DISCUSSION
This is one of the largest series describing the risk factors and outcomes of patients
affected by endocarditis due to non-HACEK GNB. We found that the genitourinary tract
as a source of infection, the presence of a CIED, and the receipt of immunosuppressive
agents are distinctive factors of endocarditis due to GNB. We also found that an MDR
TABLE 2 (Continued)
Variablea
Valueb for patients with IE due to:




All-cause in-hospital mortality 8 (13.8) 23 (13.2) 0.911
IE-related in-hospital mortality 8 (13.8) 21 (12.1) 0.731
Cumulative all-cause 1-yr mortalityc 15 (30.6) NA
Cumulative IE-related 1-yr mortalityc 11 (22.4) NA
aNVE, native valve endocarditis; PVE, prosthetic valve endocarditis; IVDU, intravenous drug user; CVC, central
venous catheter (including any of the following: arteriovenous fistula, chronic intravenous catheter, or acute
central catheter); CIED, cardiac implantable electronic device (12 permanent pacemakers and 3 cardioverter
defibrillators in patients with endocarditis due to GNB; 17 permanent pacemakers and 2 cardioverter
defibrillators in patients with other causes of endocarditis).
bValues are numbers (percentages) of patients except where otherwise indicated.
cCumulative 1-year mortality was calculated for 49 patients (8 patients who died during the hospital stay
and 41 patients with available follow-up after 1 year). NA, not available.
TABLE 3 Multivariate analysis of factors independently associated with Gram-negative IE
Factora





PLower Upper Lower Upper
Genitourinary tract 10.67 3.93 28.92 <0.001 13.60 4.63 39.93 <0.001
Immunosuppression 4.38 1.55 12.37 0.003 5.16 1.6 16.62 0.006
CIED 2.85 1.33 6.06 0.005 3.60 1.55 8.20 0.003
New regurgitation 0.37 0.17 0.77 0.007 0.39 0.17 0.90 0.027
Device-related endocarditis 3.32 1.19 9.30 0.017
CVC 2.56 1.13 5.80 0.021
Heart failure 0.48 0.25 0.94 0.003
aCIED, cardiac implantable electronic device; CVC: central venous catheter (including any of the following:
arteriovenous fistula, chronic intravenous catheter, or acute central catheter).
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etiology is the major determinant of in-hospital and long-term mortality among
patients with IE due to GNB.
The first reports of endocarditis due to non-HACEK GNB date back to some out-
breaks among injection drug users in large urban areas in the 1970s and 1980s (10–12).
Subsequently, an increasing incidence of IE due to GNB and a changing pattern of risk
factors were described among patients with health care contacts (4, 5). Most of the
knowledge about this clinical entity derived from some case series, single-center
experiences, and the ICE study, including 49 patients with IE due to non-HACEK GNB (1,
4, 13–17). Thus, our investigation represents the largest contemporary cohort of
patients with IE due to non-HACEK GNB for which data have been collected to date.
In our study, the incidence of IE due to non-HACEK GNB was 3.9%, slightly higher
than that previously observed in the ICE study (1.8%) (1). The higher percentage
probably reflects the upward trend of infections caused by GNB in recent years (18). We
identified the presence of a CIED (pacemaker or cardioverter defibrillator) and the
receipt of immunosuppressive therapy as factors independently associated with the
development of IE due to GNB. Over recent years, the growing use of CIEDs has led to
an increase in the incidence of IE due to difficult-to-treat organisms, such as methicillin-
TABLE 4 Treatment strategies for IE due to non-HACEK GNB
Antibiotic therapya No. (% of totalb)
Noncarbapenem -lactamc  aminoglycosides  fluoroquinolones 29 (50)
Penicillin or cephalosporin only 5
Non-carbapenem -lactam  aminoglycosides 14
Non-carbapenem -lactam  fluoroquinolones 8
Non-carbapenem -lactam  aminoglycosides  fluoroquinolones 2
Carbapenem  aminoglycosides  fluoroquinolones 8 (13.8)
Carbapenem only 3
Carbapenem  aminoglycosides 1
Carbapenem  fluoroquinolones 3
Carbapenem  aminoglycosides  fluoroquinolones 1
Noncarbapenem -lactam carbapenem  aminoglycosides 
fluoroquinolones
13 (22.4)
Non-carbapenem -lactam  carbapenem 4
Non-carbapenem -lactam  carbapenem  aminoglycosides 3
Non-carbapenem -lactam  carbapenem  fluoroquinolones 4
Non-carbapenem -lactam  carbapenem  aminoglycosides 
fluoroquinolones
2
Colistin-containing regimens 3 (5.2)
Colistin  carbapenem  rifampin 2
Colistin  penicillin or cephalosporin  carbapenem  rifampin 1
Other regimens 5 (8.6)
Non-carbapenem -lactam  rifampin 1
Non-carbapenem -lactam  tobramycin  clindamycin 1
Aminoglycosides  rifampin 1
Aminoglycosides  fluoroquinolones  rifampin 2
a, with or without.
bA total of 58 patients with IE due to non-HACEK GNB were studied.
cIncludes penicillin alone, penicillin–penicillinase inhibitor combinations, and third-generation cephalosporins.
TABLE 5 Cox regression analysis investigating the effect of MDR etiology on in-hospital






In-hospital mortality 21.849 2.672 178.683 0.004
1-yr mortality 4.408 1.581 12.287 0.005
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resistant Staphylococcus aureus, Candida spp., and GNB (19–22). It has been docu-
mented that a significant percentage of device-related IE cases (from 16% to 23%) are
caused by non-Staphylococcus species (23, 24), represented mostly by GNB, with a
predominance of Pseudomonas aeruginosa (24). It has also been demonstrated that, in
contrast to the pattern for infections with Gram-positive bacteria, among patients with
CIED-related IE, the GNB isolated from the pocket or infected skin tissue is highly
concordant with the strain isolated from the bloodstream (23). These findings indicate
that a clinical suspicion of IE due to non-HACEK GNB should promptly arise for patients
with CIEDs presenting with fever and evidence of pocket or lead GNB infection.
GNB remain uncommon causes of IE due to their high sensitivity to serum bacte-
ricidal activity and their inability to adhere to the endocardium (25). However, the
receipt of immunosuppressive therapy constituted a further risk factor for IE due to
GNB, suggesting that a failure in the immune system could favor valve colonization (26,
27). As expected, the genitourinary tract was the most common source of infection in
patients with endocarditis due to non-HACEK GNB, playing a role as a portal of entry
of GNB into the bloodstream (28, 29).
In our series, mortality due to IE caused by GNB was not significantly higher than
that observed among control patients with other etiologies, and these findings are
consistent with those of previous studies (reporting in-hospital and 1-year fatality rates
of 16% and 29%, respectively) (30). Of interest, MDR etiology was the factor indepen-
dently associated with short- and long-term mortality among patients affected by IE
due to non-HACEK GNB. Similarly, we observed that the administration of a noncar-
bapenem -lactam (a third-generation cephalosporin or penicillin–penicillinase inhib-
itor) was associated with a better outcome, with a significant reduction of in-hospital
mortality. Thus, the possibility of using traditional -lactams appears to be associated
with improved survival. Of importance, the greatest mortality risk occurred during the
first weeks after diagnosis; this seems to suggest a crucial role for the highly active
antibiotic therapy provided in hospital after IE diagnosis. Current guidelines of the
American Heart Association/Infectious Diseases Society of America recommend the use
of a combination antibiotic therapy with a -lactam (penicillins, cephalosporins, or
carbapenems) and either an aminoglycoside or fluoroquinolone for 6 weeks for the
treatment of endocarditis caused by non-HACEK GNB (31). However, indications for the
treatment of IE due to MDR GNB are still debated, because of the high risk of clinical
failure. In these cases, antibiotic therapy should be individualized, combination therapy
FIG 2 Kaplan-Meier plots showing in-hospital (A) and 1-year (B) survival of patients with IE caused by GNB according to multidrug-resistant etiology.
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should be provided if possible, and a consultation for the evaluation of a prompt
surgical removal of infected valves should be performed.
The major strength of our study is that it represents the largest contemporary study
describing IE due to GNB. Moreover, the SEI is a multicenter prospective study,
characteristics that increase the value of the results obtained. In contrast to the ICE
study, which compared the limited cohort of patients with IE due to GNB to all other
patients with IE (more than 2,000), we applied a matched design to reduce differences
between the two groups and, consequently, risks of bias. While previous reports merely
described isolated species in IE due to GNB, we were able to illustrate the susceptibility
patterns of isolated organisms as well, providing updated microbiology data for IE
caused by GNB. Finally, this is the first study that provides data on 1-year survival in this
cohort of patients.
Our study has some limitations. First of all, because of the rarity of infection, we were
able to investigate only a small number of patients overall. Moreover, a certain number
of patients, though only a few, were lost to 1-year follow-up. Finally, this study has not
been designed to show the superiority of a specific antibiotic regimen, and data
regarding antibiotic treatment should be confirmed in controlled randomized trials.
However, since IE due to non-HACEK GNB is a rare clinical entity, it is unlikely that such
studies will be performed. Thus, our observations could represent a valuable experience
for the selection of antibiotic therapy for IE due to GNB. Moreover, we provided the
potential explanation of this finding, which seems to be strictly related to the MDR
etiology.
In conclusion, we evaluated clinical features and outcomes of IE due to non-HACEK
GNB in a contemporary multicenter cohort. In the context of patients with IE, peculiar
features of GNB etiology include the genitourinary tract as a source of infection, the
presence of an implanted cardiac device, and receipt of immunosuppressive agents. De
novo heart failure is less typical of these patients, and sepsis signs may be more
prominent. Infection caused by an MDR strain is associated with increased mortality
rates. The use of an antibiotic regimen containing a penicillin or cephalosporin could
be suggested if a susceptible strain was isolated, but new -lactam agents with broad
activity against resistant strains could represent a therapeutic option for patients with
endocarditis due to MDR GNB strains.
MATERIALS AND METHODS
Study design and patient population. All cases of IE due to non-HACEK GNB enrolled in the Italian
Endocarditis Study (SEI) were included in this study. The SEI is a national multicenter collaboration
involving investigators from 26 centers located throughout Italy who collected all consecutive episodes
of IE identified between January 2004 and December 2011 in the participating sites (32). These included
Infectious Diseases or Internal Medicine centers located in facilities with on-site cardiac surgery. Patients
were identified prospectively using predefined, homogeneous inclusion and exclusion criteria to ensure
consecutive enrollment (32). All patients provided\informed consent to participate in the study, whose
protocol was approved by local Ethics Committees.
The diagnosis of IE was performed in accordance with the modified Duke criteria (33). Only patients
fulfilling criteria for definite IE were included in the study. Of all patients included in the SEI, those with
blood or heart valve cultures positive for a GNB were identified. To ensure that the diagnosis of
endocarditis due to GNB was accurate, the following additional criteria were applied in interpreting the
blood culture results: (i) the patient’s bacteremia had to meet the definition for persistently positive
blood cultures when the modified Duke criteria were applied; (ii) a single blood culture positive for a GNB
was not considered a minor microbiological criterion when the modified Duke criteria were applied. All
cases of IE due to HACEK organisms and all polymicrobial IE cases (IE due to GNB plus Gram-positive
bacteria or due to GNB plus Candida spp.) were excluded from the study analysis. All patients with IE due
to non-HACEK GNB were included in the study analysis representing the case group. For each case of IE
due to GNB, we randomly selected 3 patients included in the SEI cohort with definite IE due to other
infective causes (control group). The three controls were sex and age matched (2 years) with each case
of IE due to GNB.
Data collection and study definition. An ad hoc case report form was used at all sites to collect the
data (32). On admission to the hospital, all patients underwent clinical history taking, physical exami-
nation, blood tests, including multiple blood cultures, transthoracic echocardiography (TTE) and, when
needed, transesophageal echocardiography (TEE), as well as a cardiac surgery consultation. Demographic
data, comorbidities, and risk factors for endocarditis (intravenous drug use, invasive procedures in the
last 180 days, the presence of a prosthetic valve, and congenital heart disease) were collected. Concom-
itant immunosuppression therapy was defined as concomitant use of steroids (prednisolone at 0.5
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mg/kg/day or the equivalent for 1 month), chemotherapy or anti-tumor necrosis factor, cyclophos-
phamide, azathioprine, methotrexate, mycophenolate mofetil, or calcineurin inhibitor therapy. Informa-
tion about the presence of a central intravascular access device (including arteriovenous fistulas or
long-term or short-term central catheters) and cardiac implantable electronic devices (CIEDs) (both
permanent pacemakers and implantable cardioverter defibrillators) was also recorded.
IE was classified as native valve endocarditis (NVE), prosthetic valve endocarditis (PVE), or CIED-
related IE (6). The latter included pacemaker and implantable cardioverter defibrillator lead infections.
With regard to the pattern of IE acquisition, clinical cases were categorized as nosocomially acquired
(NA), nonnosocomial health care-associated (HCA), and community acquired (CA). NA-IE was defined as
IE developing in a patient hospitalized for more than 48 h before the onset of signs or symptoms
consistent with IE. HCA was defined as IE diagnosed on the basis of signs and symptoms appearing
within 48 h of admission in a patient with prior health care contacts. The latter include (i) receipt of
intravenous therapy, wound care, or specialized nursing care at home within the 30 days before the
onset of IE, (ii) attending of a hospital or hemodialysis clinic within the 30 days before the onset of IE,
(iii) hospitalization in an acute-care hospital for 2 or more days in the 90 days before the onset of IE, or
(iv) hospitalization in a nursing home or a long-term-care facility. Finally, CA IE was defined as IE
diagnosed at the time of admission (or within 48 h of admission) in a patient not fulfilling the criteria for
health care-associated infection (32).
Data about the potential complications of IE documented by the baseline echocardiogram, including
cardiac abscesses, perforation, dehiscence, new regurgitation or fistula, were recorded. Moreover, data
about other possible complications of IE, such as stroke, embolism, heart failure, septic shock, or
arrhythmias, were also collected. Data about surgical therapy, antimicrobial treatment, and the outcome
of hospitalization were also recorded.
Antibiotic treatments were classified as follows: (i) a noncarbapenem -lactam with or without
aminoglycosides and with or without fluoroquinolone, (ii) carbapenem with or without aminoglycosides
and with or without fluoroquinolones, (iii) a noncarbapenem -lactam plus carbapenem with or without
aminoglycosides and with or without fluoroquinolones, (iv) a colistin-containing regimen, or (v) other
regimens.
Data about overall and IE-attributable mortality were recorded. Mortality was attributed to IE if one
of the following criteria were satisfied: (i) blood cultures were positive for the causative pathogen at the
time of death; (ii) death occurred before the resolution of signs or symptoms of IE; (iii) death occurred
after the diagnosis of endocarditis without another explanation; (iv) death was caused by a documented
complication of infective endocarditis (refractory pulmonary edema or cardiogenic shock due to acute
regurgitation or valve obstruction; major arrhythmia; acute coronary syndrome due to vegetation
embolism or coronary obstruction); (v) autopsy findings or a death certificate indicated IE as a cause of
death, (vi) relapse of IE was documented (34).
For all patients with IE due to non-HACEK GNB, a 1-year follow-up evaluation was performed, through
a clinical visit or phone interview. During the follow-up period, a new TTE was performed for selected
patients according to patient history and physical examination.
Identification and susceptibility testing were performed using automated methods such as BacT/
Alert (bioMérieux; Marcy-L’Étiole, France) and Vitek 2 broth microdilution (bioMérieux). MDR bacteria
were defined as microorganisms nonsusceptible to at least one agent in three or more antimicrobial
categories (35).
Study outcomes. The first objective of this study was to identify risk factors associated with the
development of endocarditis due to non-HACEK GNB. To achieve this goal, a comparison between cases
and controls was performed. The second objective was to identify factors associated with in-hospital
mortality. To this end, we compared survivors and nonsurvivors with IE due to GNB, and we performed
Cox regression analysis on factors independently associated with death.
Statistical analysis. Statistical analysis was performed using commercially available statistical soft-
ware packages (SPSS, version 20.0 [SPSS, Inc., Chicago, IL] and R, version 3.0.2 [R development Core Team,
Vienna, Austria]). The chi-square test or Fisher’s exact test was used for categorical variables and the
two-tailed t test or Mann-Whitney U test for continuous variables, as appropriate. Values for continuous
and categorical variables are expressed as means  standard deviations (SD) or medians (interquartile
ranges [IQR]) and as the number and percentage of the group from which they are derived, respectively.
Multivariate analysis to identify risk factors for IE due to GNB was performed using a logistic
regression model. In the model, predictors were selected via a stepwise procedure optimizing the Akaike
Information Criterion. Odds ratios with 95% confidence intervals were calculated to evaluate the strength
of any association.
The Cox regression model was used to determine the effects of different variables on in-hospital
survival among patients with IE due to GNB. Hazard ratios with 95% CIs were calculated to evaluate the
strength of each association. The proportionality-of-hazards assumption for the Cox model has been
checked using plots of Schoenfeld residuals. Statistical significance was established at a P value of 0.05.
All reported P values are two-tailed.
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